Treatment Study for Patients with Rare Tumors

Clinical Trial Title

DART: Dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors.

Contact Information

Rush Cancer Center Clinical Trials Office

Clinical Trial Protocol Description:

This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have histologically confirmed rare cancer and/or cancer of unknown primary, that did not have a match to a molecularly-guided therapy on EAY131 National Cancer Institute (NCI)-Molecular Analysis for Therapy Choice (MATCH) protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, NCI-MATCH.
  • Have histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated cross-sectional imaging of the chest, abdomen, and pelvis.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Nicklas Pfanzelter, MD

Contact Information

Rush Cancer Center Clinical Trials Office

Location

Rush University Medical Center

1620 W Harrison St
Chicago, IL 60612

Get Directions

Clinical Trial FAQs

Find out if a clinical trial makes sense for you.

Learn more
Learn more